# US Drug Repurposing Market

> US Drug Repurposing Market Research Report By Types (Disease-centric, Target-centric, Drug-centric), By Therapeutic Area (Same Therapeutic Area, Different Therapeutic Area) and By Drug Molecules (Biologics, Small Molecule) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 14.82%
- **2024:** $ 70 Million
- **2025:** $ 80.37 Million
- **2035:** $ 320 Million
- **Key Players:** Novartis (CH), Pfizer (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), AstraZeneca (GB), Eli Lilly and Company (US), Sanofi (FR), GSK (GB), Amgen (US)

**Report ID:** MRFR/Pharma/51010-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-drug-repurposing-market-52770

---

## Market Summary

## **US Drug Repurposing Market Overview**

As per MRFR analysis, the US Drug Repurposing Market Size was estimated at 63 (USD Million) in 2023.The US Drug Repurposing Market Industry is expected to grow from 72(USD Million) in 2024 to 365 (USD Million) by 2035. The US Drug Repurposing Market CAGR (growth rate) is expected to be around 15.901% during the forecast period (2025 - 2035)

**Key US Drug Repurposing Market Trends Highlighted**

The US Drug Repurposing Market is experiencing several notable trends, driven largely by advancements in technology and the evolving landscape of healthcare. One key market driver is the increasing focus on cost-effectiveness and the need for faster drug development processes. With the rising costs of bringing new drugs to market, pharmaceutical companies are leveraging existing drugs for new applications, thereby significantly shortening development timelines. Regulatory bodies like the FDA are also playing a crucial role by encouraging drug repurposing through streamlined approval processes, which enable quicker access to therapies for patients.

Opportunities for capturing market share are growing as public and private sectors invest in research initiatives focused on repurposing. Collaborations between academia and the pharmaceutical sector are becoming more common, fostering innovation and accelerating discovery. The recent surge in interest in drugs considered for repurposing due to the COVID-19 pandemic has further illuminated the potential for existing medications to provide new treatments for various conditions.  Additionally, there is an increasing emphasis on data-driven approaches in the US Drug Repurposing Market, with artificial intelligence and machine learning being utilized to identify potential candidates for repurposing.

This trend showcases how technology can enhance drug discovery and optimize the treatment pipeline. Furthermore, patient advocacy groups are becoming more vocal in promoting the benefits of repurposed drugs, increasing awareness and acceptance among healthcare providers. Overall, the convergence of cost pressures, regulatory support, technological advancements, and patient advocacy is shaping a dynamic environment in the US Drug Repurposing Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**US Drug Repurposing Market Drivers**

**Increasing Prevalence of Chronic Diseases**

The rising incidence of chronic illnesses, including diabetes, cancer, and cardiovascular disorders in the general population, is a major factor propelling the US drug repurposing market industry. About 6 out of 10 people in the US have a chronic illness, and 4 out of 10 have two or more, according to the Centers for Disease Control and Prevention (CDC). Due to the pressing demand for efficient therapies brought on by the rise in chronic illnesses, scientists and pharmaceutical corporations are looking into medication repurposing as a potential way to swiftly develop new therapeutic choices.

Large pharmaceutical companies like Pfizer and Johnson & Johnson are spending more money on R&D projects that aim to repurpose current medications for novel therapeutic uses. This strategy highlights the industry's development potential in the upcoming years by cutting down on the time to market as well as the total expenses related to introducing new medications into clinical use.

**Advancements in Computational Drug Discovery**

Modern advancements in computational drug discovery and artificial intelligence (AI) are fueling growth in the US Drug Repurposing Market Industry. Increased computational power allows for the analysis of vast datasets, leading to the identification of new uses for existing drugs. The National Institutes of Health (NIH) has reported a 200% increase in the use of computational techniques in drug repurposing studies over the last five years. Companies such as IBM, with its Watson for Drug Discovery, are leveraging AI to uncover potential new uses for existing medications.

These advancements enable faster identification of candidates for repurposing, thus accelerating the process of bringing treatments to patients, showcasing a significant driver for market expansion.

**Growing Investment in Drug Repurposing Initiatives**

The rise in funding for drug repurposing initiatives plays a vital role in the US Drug Repurposing Market Industry. Government entities and venture capital firms are increasingly providing financial support for research aimed at repurposing existing drugs. For instance, the National Institutes of Health announced a substantial federal grant program aimed at repurposing drugs for community-level health challenges, which has already allocated over USD 200 million since its inception. This financial backing encourages academic institutions and pharmaceutical companies to collaborate on repurposing projects, leading to innovative treatments that address urgent health needs efficiently.

As a result, this increasing level of investment is propelling the market forward.

**Regulatory Support for Drug Repurposing**

A favorable regulatory environment supporting drug repurposing significantly contributes to the growth of the US Drug Repurposing Market Industry. Regulatory bodies like the Food and Drug Administration (FDA) have established programs such as the Orphan Drug Designation and the Fast Track designation, which expedite the review process for repurposed drugs. In recent years, the FDA has received a notable increase in repurposed drug applications, with over 30% of new drug approvals in the last decade involving previously approved therapies.

This level of regulatory encouragement not only streamlines the approval process but also enhances the attractiveness of drug repurposing strategies, further establishing it as a key driver for the market.

**US Drug Repurposing Market Segment Insights**

**Drug Repurposing Market Types Insights  **

The US Drug Repurposing Market has gained significant attention due to its potential to expedite treatment options and optimize the existing drug pipeline. This market can be broadly classified into three primary types: Disease-centric, Target-centric, and Drug-centric approaches. The Disease-centric type focuses on identifying existing medications that can be utilized to treat different conditions than originally intended, often leading to breakthroughs in therapies for chronic and complex diseases. This approach is pivotal as it leverages existing data and safety profiles, potentially shortening the time for new treatments to reach patients.

The Target-centric approach targets specific biological mechanisms underlying diseases, allowing pharmaceuticals to explore alternative therapies quickly and efficiently by repurposing existing drugs that interact with certain pathways. This type of approach is significant for driving innovation in precision medicine, especially in areas with high unmet medical needs. Meanwhile, the Drug-centric approach centers on repurposing drugs to treat new indications, highlighting the adaptability of compounds that have already undergone extensive testing for safety and efficacy.

Given that the US is a leading hub for pharmaceutical R&D, these approaches support the growing market, spurred by favorable governmental policies and funding initiatives aimed at enhancing drug repurposing strategies. The overall surge in adoption of these strategies is driven by the public's demand for more rapid solutions to emerging health crises, such as antiviral therapies in response to pandemics, thus reinforcing the significance of the Drug Repurposing Market in the US healthcare landscape.

Each type within the segmentation presents unique opportunities, challenges, and methodologies that cater to a variety of therapeutic needs, ultimately contributing to a more responsive healthcare system.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Drug Repurposing Market Therapeutic Area Insights  **

The US Drug Repurposing Market within the Therapeutic Area segment is rapidly evolving, driven by the increasing demand for innovative and cost-effective treatment solutions. This segment encompasses various approaches, notably Same Therapeutic Area and Different Therapeutic Area strategies. The Same Therapeutic Area approach focuses on identifying new uses for existing drugs that target the same diseases, contributing to enhanced treatment protocols and patient outcomes while minimizing Research and Development costs. Conversely, the Different Therapeutic Area strategy expands the scope of drug applications to treat entirely distinct diseases, leveraging previously established safety profiles to streamline the development process.

This diversification is gaining traction as healthcare systems strive for improved efficiency and better resource allocation. Coupled with increasing regulatory support for repurposed drugs, these strategies position themselves as vital components in addressing unmet medical needs in the US. With a clear focus on therapeutic efficacy and safety, Drug Repurposing emerges as a promising avenue to optimize healthcare delivery and improve patient access to effective treatments. The ongoing evolution of this market is expected to provide significant opportunities for growth and innovation in the coming years.

**Drug Repurposing Market Drug Molecules Insights  **

The 'US Drug Repurposing Market', focusing on Drug Molecules encompasses various crucial components that drive innovation in therapeutic applications. Biologics and Small Molecules are the primary contributors within this segment, catering to different medical needs. Biologics, derived from living organisms, are essential for treating complex diseases, including autoimmune disorders and certain types of cancers, thus showing substantial growth due to their targeted approach. Small Molecules dominate the pharmaceutical landscape, being crucial for a broad spectrum of diseases, including infectious diseases and chronic conditions, given their ability to penetrate cells easily.

The growth in Drug Molecules is supported by advancements in Research and Development, enhanced regulatory approval processes, and a growing shift towards personalized medicine. Moreover, the rising prevalence of various diseases and the need for cost-effective treatment options further drive market dynamics, highlighting the significance of Drug Molecules. The ongoing trend in repurposing existing drugs is expected to accelerate the pace of delivery and reduce time to market, making the Drug Molecules segment a vital area in the US Drug Repurposing Market.

**US Drug Repurposing Market Key Players and Competitive Insights**

The US Drug Repurposing Market is experiencing significant growth, characterized by an increasing number of pharmaceutical companies and research institutions exploring new therapeutic applications for existing medications. This market is driven by the potential for quicker, more cost-effective drug development compared to traditional drug discovery methods, which often involve lengthy and expensive processes. 

Competitive insights reveal that numerous organizations are actively pursuing repurposing strategies, which capitalize on already established safety profiles of drugs, thereby allowing them to identify new treatment options for various diseases, including rare and complex conditions. As innovation in biotechnology and pharmaceuticals continues to grow, the landscape of drug repurposing signifies a paradigm shift, encouraging collaborations among various stakeholders, including academia, government agencies, and the private sector. AstraZeneca is a prominent player in the US Drug Repurposing Market, leveraging its extensive research capabilities and robust pipeline of pharmaceuticals.

The company is well-known for its commitment to innovation, which plays a crucial role in its drug repurposing efforts. AstraZeneca has a strong foundation built on significant therapeutic expertise across multiple disease areas, such as oncology, cardiovascular, and respiratory diseases, enabling it to identify new indications for existing drugs. 

With a focus on strategic partnerships and collaborations, AstraZeneca maximizes its resources and expands its reach in discovering novel usages for established products, an approach that enhances its competitive edge in the market. The company’s reputation for prioritizing patient needs underlies its strategies in determining how to best reposition drugs effectively within the US market. Merck is another key player in the US Drug Repurposing Market, known for its established portfolio of pharmaceuticals and strong emphasis on research and development.

The company has made substantial investments in finding new therapeutic applications for its existing drugs, aiming to promote advancements in treatment options. Merck’s key products already include several that have shown potential for repurposing, further solidifying its position within the market. By focusing on therapeutic areas such as infectious diseases and oncology, Merck has been able to leverage its scientific expertise to revitalize older compounds. 

The company actively pursues strategic mergers and acquisitions to bolster its capabilities in drug repurposing, thereby enhancing its market presence and fortifying its strengths in delivering innovative healthcare solutions. Through its dedication to continuous exploration and application of existing medicines, Merck contributes significantly to the dynamic landscape of the US Drug Repurposing Market.

**Key Companies in the US Drug Repurposing Market Include**

**US Drug Repurposing Market Industry Developments**

Significant developments in the US Drug Repurposing Market have emerged recently, particularly driven by large pharmaceutical companies such as AstraZeneca, Merck, and Roche, focusing on the potential of existing drugs for new therapeutic uses. In October 2023, Amgen announced a substantial partnership with a biotech firm to advance its drug repurposing initiatives, targeting conditions like neurodegenerative diseases. Furthermore, Bristol Myers Squibb has been actively exploring the potential of its existing oncology drugs to treat autoimmune disorders, demonstrating a growing trend in the industry.

Notably, Eli Lilly reported a successful trial of a repurposed diabetes medication for treating Alzheimer's disease in August 2023, signaling a pivotal shift in therapeutic applications.

 The market valuation for US Drug Repurposing continues to rise, fueled by innovations and cost-cutting strategies associated with leveraging existing therapies. Additionally, in September 2023, Regeneron Pharmaceuticals acquired a small company specializing in repurposing therapies for genetic disorders, enhancing its pipeline. Overall, the US Drug Repurposing Market remains vibrant, with ongoing investments and strategic collaborations among major players like Johnson and Johnson, Gilead Sciences, and AbbVie, fostering a robust environment for drug innovation.

**Drug Repurposing Market Segmentation Insights**

## Market Drivers

### Aging Population

The demographic shift towards an aging population in the US is a critical driver for the drug repurposing market. As individuals age, they often experience multiple chronic conditions, necessitating a diverse range of therapeutic options. The drug repurposing market can address these needs by providing existing medications that may be effective for new indications. For instance, the prevalence of Alzheimer's disease and other age-related disorders is increasing, creating a demand for innovative treatment strategies. This demographic trend suggests that the market for repurposed drugs could expand significantly, as healthcare providers look for effective solutions to manage complex health issues in older adults.

### Rising Healthcare Costs

The escalating costs associated with healthcare in the US are driving interest in the drug repurposing market. As traditional drug development can exceed $2.6 billion and take over a decade, repurposing existing drugs offers a more cost-effective alternative. This approach not only reduces the financial burden on healthcare systems but also expedites the availability of treatments. The drug repurposing market is thus positioned to benefit from the need for affordable therapies, as stakeholders seek to optimize resources while addressing unmet medical needs. Furthermore, the potential for repurposed drugs to enter the market more rapidly can lead to significant savings for both patients and healthcare providers, making this a compelling driver for growth.

### Patient-Centric Approaches

The shift towards patient-centric healthcare models is influencing the drug repurposing market. Patients are increasingly involved in treatment decisions, and there is a growing demand for therapies that are not only effective but also tailored to individual needs. The drug repurposing market can leverage this trend by offering existing medications that have demonstrated efficacy in diverse patient populations. This approach not only enhances patient satisfaction but also aligns with the broader movement towards personalized medicine. As healthcare providers seek to improve outcomes and patient experiences, the repurposing of drugs presents a promising avenue for meeting these evolving expectations.

### Technological Advancements

Technological innovations in data analytics and artificial intelligence are transforming the drug repurposing market. These advancements enable researchers to analyze vast datasets, identifying potential new uses for existing drugs more efficiently. The drug repurposing market is likely to see increased activity as machine learning algorithms and bioinformatics tools facilitate the discovery of novel therapeutic applications. For example, AI-driven platforms can predict drug interactions and efficacy, streamlining the repurposing process. This technological evolution not only enhances the speed of drug development but also reduces the associated costs, making it an attractive option for pharmaceutical companies and investors alike.

### Increased Focus on Rare Diseases

The growing emphasis on rare diseases in the US healthcare landscape is propelling the drug repurposing market. Many rare conditions lack effective treatments, and repurposing existing drugs can provide a viable solution. The drug repurposing market is increasingly recognized for its potential to address these unmet needs, as it allows for quicker access to therapies that may already be approved for other indications. This focus aligns with regulatory incentives aimed at encouraging the development of treatments for rare diseases, further stimulating interest in repurposed drugs. As awareness and advocacy for rare diseases grow, the market for repurposed therapies is expected to expand.

## Future Outlook

The [Drug Repurposing Market](https://www.marketresearchfuture.com/reports/drug-repurposing-market-22086) is projected to grow at a 14.82% CAGR from 2025 to 2035, driven by technological advancements, regulatory support, and increasing healthcare costs.

**New opportunities:**

- Development of AI-driven drug screening platforms
- Partnerships with biotech firms for accelerated trials
- Expansion into niche therapeutic areas with unmet needs

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Disease-centric (Largest) vs. Target-centric (Fastest-Growing)

In the US drug repurposing market, the market share distribution shows that the Disease-centric approach holds the largest segment, effectively addressing multiple conditions and attracting significant investment. This segment's focus on utilizing existing drugs for known diseases allows for quicker development timelines, gaining a larger share due to its efficiency and established protocols in the industry.

On the other hand, the Target-centric segment is recognized as the fastest-growing within the market. Its innovative strategy focuses on specific molecular targets, encouraging precision medicine approaches. The rise in personalized therapies and advancements in genomic technologies are driving this trend, as stakeholders prioritize treatments that are tailored to individual patient profiles.

Disease-centric: Dominant vs. Target-centric: Emerging

The Disease-centric approach dominates the US drug repurposing market, characterized by its ability to quickly pivot existing medications to treat a range of diseases, resulting in faster therapeutic availability. This segment leverages extensive clinical data and historical efficacy, mitigating the risks associated with new drug development. Conversely, the Target-centric approach is emerging rapidly, employing cutting-edge research methodologies such as high-throughput screening and biomarker development. This segment caters to the growing demand for personalized medicine, with a focus on targeting specific biological pathways. As healthcare becomes more individualized, the Target-centric segment is expected to gain prominence, driven by innovations in technology and a deeper understanding of disease mechanisms.

### By Therapeutic Area: Same Therapeutic Area (Largest) vs. Different Therapeutic Area (Fastest-Growing)

The market for therapeutic areas in the US drug repurposing market showcases a diverse range of applications, with a significant share attributed to repurposing drugs within the same therapeutic area. This strategy not only maximizes existing drug profiles but also facilitates faster regulatory approvals due to recognized safety profiles. Meanwhile, repurposing drugs for different therapeutic areas offers a growing opportunity as researchers and companies explore innovative solutions to address unmet medical needs across various diseases.

Growth trends indicate a robust increase in the repurposing of drugs for different therapeutic areas, driven by advancements in biotechnology and an urgent demand for novel treatment options. This trend is fueled by a rising focus on personalized medicine and the efficiency of utilizing existing drugs, which often allows for reduced development timelines. Consequently, while the same therapeutic area remains dominant, the different therapeutic area is emerging as the fastest-growing segment, attracting substantial investment and interest from pharmaceutical companies.

Same Therapeutic Area: Dominant vs. Different Therapeutic Area: Emerging

The therapeutic area segment characterized by repurposing drugs within the same area is considered dominant, leveraging existing therapeutic profiles to enhance efficacy and reduce risks. This approach is particularly prominent in chronic disease management where established drugs can be repositioned with minimal alterations. Conversely, the emerging segment of repurposing drugs into different therapeutic areas is gaining traction. This strategy harnesses innovative technologies and extensive research to discover new applications for existing drugs, addressing various health challenges. Market participants are increasingly investing in this segment, drawn by the potential for high returns from rapid entry into new treatment markets and addressing pressing healthcare demands across differing patient populations.

### By Drug Molecules: Biologics (Largest) vs. Small Molecule (Fastest-Growing)

In the US drug repurposing market, the distribution of market share between biologics and small molecules reveals a significant dominance by biologics, which hold a considerable share due to their complex nature and targeted therapeutic applications. Small molecules, while not as dominant, have been rapidly gaining traction as innovative therapeutic agents in various diseases, especially as they demonstrate versatility in repurposing for new indications.

The growth trends in this segment are largely driven by increasing investments in biopharmaceutical research and development. Alongside advancements in biotechnology, there is a rising emphasis on personalized medicine which favors biologics for their ability to target specific disease pathways. Meanwhile, the small molecule segment is growing rapidly, propelled by advancements in synthetic chemistry and a flourishing interest in novel drug delivery systems that enhance their efficacy and safety profiles.

Biologics (Dominant) vs. Small Molecule (Emerging)

Biologics represent the dominant segment in the US drug repurposing market, characterized by large-scale production through biological processes and often requiring sophisticated manufacturing techniques. They include therapeutic proteins, monoclonal antibodies, and vaccines, which excel in treating complex conditions such as cancers and autoimmune disorders. Conversely, small molecules are emerging as a competitive force, known for their ease of manufacturing and comprehensive mechanism of action. They dominate a wide range of indications due to their ability to penetrate cells easily and inhibit specific biological pathways. The ongoing research to discover new applications for existing small molecules is contributing significantly to their rise within the market.

## Competitive Benchmarking

The drug repurposing market is characterized by a dynamic competitive landscape, driven by the need for cost-effective therapeutic solutions and accelerated drug development timelines. Major players such as Pfizer (US), Bristol-Myers Squibb (US), and Johnson & Johnson (US) are strategically positioned to leverage their extensive research capabilities and established market presence. Pfizer (US) focuses on innovation through its robust pipeline of repurposed drugs, while Bristol-Myers Squibb (US) emphasizes strategic partnerships to enhance its research capabilities. Johnson & Johnson (US) adopts a multifaceted approach, integrating digital transformation into its operations to streamline drug development processes. Collectively, these strategies foster a competitive environment that prioritizes rapid innovation and collaboration.Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a diverse range of therapeutic options, although the presence of dominant firms like Pfizer (US) and Johnson & Johnson (US) suggests a concentration of resources and expertise that shapes overall market trends.

In October  Pfizer (US) announced a collaboration with a leading biotech firm to explore the repurposing of existing therapies for rare diseases. This strategic move is significant as it not only expands Pfizer's portfolio but also aligns with the growing trend of addressing unmet medical needs through innovative approaches. The partnership is expected to enhance research capabilities and accelerate the development of new treatment options, thereby reinforcing Pfizer's competitive position in the market.

In September  Bristol-Myers Squibb (US) launched a new initiative aimed at repurposing its existing oncology drugs for use in treating autoimmune diseases. This initiative reflects a strategic pivot towards leveraging existing assets to address broader therapeutic areas. By repurposing established drugs, the company aims to reduce development costs and timeframes, which could potentially lead to quicker patient access to new therapies, thus enhancing its market competitiveness.

In August  Johnson & Johnson (US) unveiled a digital platform designed to facilitate the identification of potential drug repurposing opportunities. This platform utilizes advanced data analytics and machine learning to streamline the drug discovery process. The introduction of such technology underscores the company's commitment to digital transformation and positions it favorably in a market increasingly driven by data-driven decision-making.

As of November  current competitive trends in the drug repurposing market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI). Strategic alliances are becoming increasingly vital, as companies recognize the need for collaborative efforts to enhance research and development capabilities. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these elements will be better positioned to thrive in an increasingly complex market.

## Recent News & Developments

Significant developments in the US Drug Repurposing Market have emerged recently, particularly driven by large pharmaceutical companies such as AstraZeneca, Merck, and Roche, focusing on the potential of existing drugs for new therapeutic uses. In October 2023, Amgen announced a substantial partnership with a biotech firm to advance its drug repurposing initiatives, targeting conditions like neurodegenerative diseases. Furthermore, Bristol Myers Squibb has been actively exploring the potential of its existing oncology drugs to treat autoimmune disorders, demonstrating a growing trend in the industry.

Notably, Eli Lilly reported a successful trial of a repurposed diabetes medication for treating Alzheimer's disease in August 2023, signaling a pivotal shift in therapeutic applications.

 The market valuation for US Drug Repurposing Market continues to rise, fueled by innovations and cost-cutting strategies associated with leveraging existing therapies. Additionally, in September 2023, Regeneron Pharmaceuticals acquired a small company specializing in repurposing therapies for genetic disorders, enhancing its pipeline. Overall, the US Drug Repurposing Market remains vibrant, with ongoing investments and strategic collaborations among major players like Johnson and Johnson, Gilead Sciences, and AbbVie, fostering a robust environment for drug innovation.

## Report Scope

| MARKET SIZE 2024 | 70.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 80.37(USD Million) |
| MARKET SIZE 2035 | 320.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.82% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Novartis (CH), Pfizer (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), AstraZeneca (GB), Eli Lilly and Company (US), Sanofi (FR), GSK (GB), Amgen (US) |
| Segments Covered | Type, Therapeutic Area, Drug Molecules |
| Key Market Opportunities | Emerging technologies enhance efficiency in drug repurposing, addressing unmet medical needs and regulatory pathways. |
| Key Market Dynamics | Growing emphasis on regulatory compliance drives innovation and competition in the drug repurposing market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US drug repurposing market in 2024?**
A: The market valuation was $70.0 Million in 2024.

**Q: What is the projected market valuation for the US drug repurposing market by 2035?**
A: The projected valuation for 2035 is $320.0 Million.

**Q: What is the expected CAGR for the US drug repurposing market during the forecast period 2025 - 2035?**
A: The expected CAGR is 14.82% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the US drug repurposing market?**
A: Key players include Novartis, Pfizer, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, Eli Lilly and Company, Sanofi, GSK, and Amgen.

**Q: What are the segment valuations for the Type category in the US drug repurposing market?**
A: Segment valuations for Type include Disease-centric at $90.0 Million, Target-centric at $120.0 Million, and Drug-centric at $110.0 Million.

**Q: How does the Therapeutic Area segment perform in the US drug repurposing market?**
A: The Therapeutic Area segment shows valuations of $180.0 Million for Same Therapeutic Area and $140.0 Million for Different Therapeutic Area.

**Q: What are the valuations for the Drug Molecules segment in the US drug repurposing market?**
A: The Drug Molecules segment includes Biologics at $90.0 Million and Small Molecule at $230.0 Million.

**Q: How does the US drug repurposing market compare to its projected growth by 2035?**
A: The market is expected to grow from $70.0 Million in 2024 to $320.0 Million by 2035, indicating substantial growth.

**Q: What factors contribute to the growth of the US drug repurposing market?**
A: Factors contributing to growth may include advancements in research, increased investment from key players, and a rising demand for innovative therapies.

**Q: What is the significance of drug repurposing in the pharmaceutical industry?**
A: Drug repurposing offers potential benefits such as reduced development time and costs, which may enhance the efficiency of bringing new treatments to market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-drug-repurposing-market-52770*